CNBC's "Fast Money" Apple Reports Results… And Novo Nordisk’s Obesity Drug Price Cut 5/2/24
May 2, 2024
Exploring Apple's financial performance, Novo Nordisk's price cuts for obesity drugs, and competition in the biopharma market. Delving into AI potential, company valuation, upcoming earnings reports, and market trends. Analyzing pharmaceutical market dynamics, tech earnings reviews, and potential acquisitions. Speculation on stock prices and an advertisement for Capella University's flex path learning.
AI Snips
Chapters
Transcript
Episode notes
Buyback Impact
- Apple's historic $110 billion buyback outweighs a 10% drop in iPhone sales, boosting shares by 7%.
- This buyback, while massive, may not be sustainable for long-term growth.
Need for Innovation
- Apple needs innovation to combat declining iPhone sales and competition from China.
- The upcoming Worldwide Developers Conference in June may offer a glimpse into their AI strategy.
Apple and WWDC
- Consider Apple's performance leading up to the June Worldwide Developers Conference.
- Evaluate if their potential AI developments justify their current valuation.